QUESTION 67 Allocating transaction price – standalone selling prices are not directly observable Biotech enters into an arrangement to provide a license and research services to Pharma. The license and the services are each distinct and therefore accounted for as separate performance obligations, and neither is sold individually. What factors might Biotech consider when estimating the standalone selling prices for these items?